Page 74 - Clinical Development News Today

A small molecule kinase inhibitor has been trialed in humans for the first time as part of a glioblastoma treatment study.

Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy MADRID, Oct. 21, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 2 randomized, open-label THOR-2 study evaluating BALVERSA® versus investigator […]

Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical...

Feedback has been submitted to the US Food and Drug Administration (FDA) with guidelines intended for sponsors of clinical trials related to psychedelic compounds.

/PRNewswire/ -- The "Peptide Drug Conjugates Market Size, Share & Trends Analysis Report By Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12, Other...

– Two-Year Resistance Analysis from CAPELLA Pivotal Trial Reinforces Sunlenca as a Person-Centered Option in Combination with an Optimized Background Regimen – – Latest Research Highlights...

Dave Hine is the senior director of sales and engineering at Greenphire. He has been reflecting on his time at DPharm and the collaborative approach to life sciences.

First readout of two-year data from long-term extension study INDIANAPOLIS, Oct. 20, 2023 /PRNewswire/ -- Patients with moderate-to-severe atopic dermatitis who continued treatment with...

Matteo Lai was part of a panel at DPharm in Boston this year, it was called working together to accelerate the adoption of digital biomarkers in clinical trials.

First readout of two-year data from long-term extension study ...